NCT06874192View on ClinicalTrials.gov

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

April 1, 2026

Conditions
Statin Adverse Reaction
Interventions
DRUG

Low-dose colchicine at 0.5mg daily

LODOCO is low-dose colchicine at 0.5mg daily, ii is an FDA approved anti-inflammatory drug, to prevent cardiovascular events in patients with coronary artery disease. LODOCO works by inhibiting microtubule formation and reducing the activity of neutrophils, which play a key role in inflammation.

OTHER

Placebo

Matching placebo

Trial Locations (1)

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER